The FDA announced on February 6, 2026 that it intends to take action restricting GLP-1 active pharmaceutical ingredients — such as semaglutide — used in non-FDA-approved compounded drugs that are mass-marketed to consumers, per the FDA, 2026. The announcement directly targets the business model of telehealth sellers offering cheap compounded copies of drugs like Wegovy and Ozempic.
This site publishes information, not medical advice; decisions about weight-loss medication belong with you and your clinician. The agency's move concerns how these products are made and marketed, not a claim about any individual's care.
Why is the FDA acting now?
Compounded drugs are not FDA-approved: the agency does not verify their quality, safety, or efficacy before they reach consumers, per the FDA, 2026. In the February 6 statement, Commissioner Martin A. Makary said the agency cannot verify those qualities for the unapproved products and cited potential violations of the Federal Food, Drug, and Cosmetic Act. The step builds on warning letters the FDA sent in fall 2025 over misleading direct-to-consumer advertising of compounded GLP-1s.
The announcement also draws new marketing lines. Companies may not claim a compounded drug is a generic version, is identical to an FDA-approved drug, or is "clinically proven to produce results," per the FDA, 2026. Reuters reported the plan as a direct challenge to mass-market compounded GLP-1 offerings, a category that grew rapidly after semaglutide shortages ended in early 2025.
Related stories: FDA Sends 30 Warning Letters to Telehealth GLP-1 Sellers · Hims & Hers Posts $2.35B Year as GLP-1 Scrutiny Grows.
What happens to telehealth sellers?
The FDA said it may pursue legal action — including seizure and injunction — "without further notice" if violations are not corrected, per the FDA, 2026. For companies built on compounded semaglutide subscriptions, the practical options are narrowing: pivot to FDA-approved branded drugs, change marketing claims, or exit the category. Patients currently buying compounded GLP-1s online should expect sellers to revise offerings and should discuss approved alternatives with their prescriber.
What this changes for readers
If you buy a weight-loss drug online, the brand behind the vial matters more than ever. An FDA-approved product has been reviewed for quality and effect; a compounded copy has not, per the FDA, 2026. Before you reorder from a telehealth site, check whether what ships is an approved medicine, and bring the vial or packaging to your clinician or pharmacist if you are unsure.
The bottom line
On February 6, 2026, the FDA said it will restrict GLP-1 ingredients used in non-approved compounded drugs and will not tolerate marketing that frames them as identical to approved medicines, per the FDA, 2026. If you use or are considering a compounded GLP-1, the next sensible step is a conversation with your clinician about FDA-approved options.